CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Cypherpunk Technologies Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Cypherpunk Technologies Inc
47 Thorndike Street, Suite B1-1
Phone: (617) 252-4343p:617 252-4343 CAMBRIDGE, MA  02142  United States Ticker: CYPHCYPH
Business Summary
Cypherpunk Technologies Inc., formerly Leap Therapeutics, Inc., is engaged in developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The Company focuses on the development of sirexatamab and FL-501 to treat patients with cancer. Zcash is a privacy-preserving blockchains, launched as a fork of Bitcoin with advanced cryptography that enables selective transparency. Zcash has introduced privacy technology through the use of zero-knowledge proofs (zk-SNARKs), allowing transactions to be verified without revealing sender, receiver, or amount. FL-501 is a potential class antibody designed to neutralize GDF-15 and prevent the binding to its receptor. sirexatamab (DKN-01), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. Sirexatamab is being developed in patients with esophagogastric, gynecologic, and colorectal cancers.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202512/31/2024YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board KhingOei 49 11/10/2025 11/10/2025
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director Douglas E.Onsi 56 4/1/2020 1/1/2011
Chief Investment Officer, Director WilliamMcevoy 29 11/11/2025 11/11/2025
7 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Macrocure Ltd. Kiryat Matalon, 25, Ha-Sivim Petach Tikva Israel
Flame Biosciences, Inc. 555 Madison Avenue New York City NY United States

Business Names
Business Name
CYPH
Flame Biosciences LLC
GITR, Inc.
4 additional Business Names available in full report.

General Information
Number of Employees: 52 (As of 12/31/2024)
Outstanding Shares: 56,651,840 (As of 10/24/2025)
Shareholders: 41
Stock Exchange: NASD
Federal Tax Id: 274412575
Fax Number: (302) 636-5454
Email Address: info@leaptx.com


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, November 27, 2025